Last year, Daewoong and
its U.S. partner Alphaeon filed for FDA approval for its BTX product, Nabota in
USA. Medytox will face competitions of Daewoong in the US market.
Accordingly, Medytox filed
a lawsuit in USA alleging Daewoong of stealing its strain of the Botulinum
toxin. But the plaintiff could not succeed to block the competitor’s business
in USA through the lawsuit because the lawsuit case was not successful.
On Oct. 12, 2017, the
Superior Court of California in Orange County dismissed the case with ruling that
the case should be settled in Korea. The court stated that "the court
finds that Korea is an alternative suitable forum in which an action can be
brought against all defendants."
Furthermore, the US court
decided that "if it turns out that the alternative forum is not suitable
after all, this court has the power to lift the stay and proceed with the
action in the original forum, the court sets a status conference on a stayed
matter for April 13, 2018."
According to their press release,
Medytox will file a lawsuit against Daewoong in Korea soon.